Management of hepatorenal syndrome

Pharmacology and Therapeutics

Volumn 119, Issue 1, 2008, Pages 1-6

  McCormick, P A ^a,b   Donnelly, Carmel ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Hepatorenal syndrome; MARS; Midodrine; Octreotide; Ornipressin; Renal failure; Terlipressin; TIPS

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CREATININE; DOPAMINE; FUROSEMIDE; GADOLINIUM; MIDODRINE; NORADRENALIN; OCTREOTIDE; OFLOXACIN; ORNIPRESSIN; PENTOXIFYLLINE; PLASMA SUBSTITUTE; TERLIPRESSIN; VASOPRESSIN DERIVATIVE;

ALCOHOL LIVER DISEASE; ASCITES; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HEMOFILTRATION; HEPATORENAL SYNDROME; HUMAN; HYDRATION; HYPONATREMIA; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY VEIN; LIVER SUPPORT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MOLECULAR ABSORBENT RECIRCULATING SYSTEM THERAPY; MONOTHERAPY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACENTESIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SHUNTING; SPLANCHNIC BLOOD FLOW; TRANSJUGULAR INTRAHEPATIC STENT SHUNT; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS;

EID: 46349084032     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.02.012     Document Type: Review

References (62)

1. Akriviadis E., Botla R., Briggs W., Han S., Reynolds T., and Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
2. Alessandria C., Venon W.D., Marzano A., Barletti C., Fadda M., and Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14 (2005) 1363-1368
3. Angeli P., Volpin R., Gerunda G., Craighero R., Roner P., Merenda R., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
4. Arroyo V., Gines P., Gerbes A.L., Dudley F.J., Gentilini P., Laffi G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23 (1996) 164-176
5. Brensing K.A., Textor J., Perz J., Schiedermaier P., Raab P., Strunk H., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome; a phase II study. Gut 47 (2000) 288-295
6. Campbell M.S., Kotlyar D.S., Brensinger C.M., Lewis J.D., Shetty K., Bloom R.D., et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 11 (2005) 1048-1055
7. Cardenas A., Gines P., Uriz J., Bessa X., Salmeron J.M., Mas A., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34 (2001) 671-676
8. Cohn J.N., Tristani F.E., and Khatri I.M. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man. Circulation 38 (1968) 151-157
9. Colle I., Durand F., Pessione F., Rassiat E., Bernuau J., Barriere E., et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17 (2002) 882-888
10. Donnellan F., Cullen G., Hegarty J.E., and McCormick P.A. Ischaemic complications of glypressin in liver disease: a case series. Br J Clin Pharmacol 64 (2007) 550-552
11. Duvoux C., Zanditenas D., Hezode C., Chauvat A., Monin J.-L., Roudat-Thoraval F., et al. Effect of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36 (2002) 374-380
12. Epstein M., Berk D.P., Hollenberg N.K., Adams D.F., Chalmers T.C., Abrams H.L., and Merrill J.P. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49 (1970) 175-185
13. Esrailian E., Pantangco E.R., Kyulo N.L., Hu K.-Q., and Runyon B.A. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52 (2007) 742-748
14. Fabrizi F., Dixit V., and Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 24 (2006) 935-944
15. Fasolato S., Angeli P., Dallagnese L., Maresio G., Zola E., Mazza E., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45 (2007) 223-229
16. Fernandez J., Navasa M., Planas R., Montoliu S., Monfort D., Soriano G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133 (2007) 818-824
17. Gerbes A.L., and Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology 41 (2005) 217
18. Gines A., Escorsell A., Gines P., Salo J., Jimenez W., Inglada L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
19. Gines P., Guevara M., Arroyo V., and Rodes J. Hepatorenal syndrome. Lancet 362 (2003) 1819-1827
20. Gluud L.L., Kjaer M.S., and Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 18 4 (2006) CD005162
21. Gonwa T.A., Morris C.A., Goldstein R.M., Husberg B.S., and Klintmalm G.B. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Tranplantation 51 (1991) 428-430
22. Guevara M., Gines P., Fernandez-Esparrach G., Sort P., Salmeron J.M., Jimenez W., et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27 (1998) 35-41
23. Guevara M., Gines P., Bandi J.C., Gilabert R., Sort P., Jimenez W., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
24. Gulberg V., Bilzer M., and Gerbes A.L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30 (1999) 870-875
25. Halimi C., Bonnard P., Bernard B., Mathurin P., Mofredj A., di Martino V., et al. Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14 (2002) 153-158
26. Heyndrickz G.R., Boettcher D.H., and Vatner S.F. Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 231 (1976) 1579-1587
27. Iwatsuki S., Popovtzer M.M., Corman J.L., Ishikawa M., Putnam C.W., Katz F.H., et al. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med 289 (1973) 1155-1159
28. Jalan R., Forrest E.H., Redhead D.N., Dillon J.F., and Hayes P.C. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?. Gut 40 (1997) 670
29. Kalambokis G., Economou M., Fotopoulos A., AlBokharhii J., Pappas C., Katsaraki A., et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 100 (2005) 879-885
30. Kam P.C.A., Williams S., and Yoong F.F.Y. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 59 (2004) 993-1001
31. Kiser T.H., Fish D.N.O., Jung R., MacLaren R., and Parikh C.R. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 20 (2005) 1813-1820
32. Koppel M.H., Coburn J.W., Mims M.M., Goldstein H., Boyle J.D., and Rubini M.E. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280 (1969) 1367-1371
33. Mackle I.J., Swann D.G., and Cook B. One year outcome of intensive care patients with decompensated alcoholic liver disease. Br J Anaesthesia 97 (2006) 496-498
34. Marik P.E., Wood K., and Starzl T.E. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 21 (2006) 478-482
35. McCormick P.A., Dick R., and Burroughs A.K. Review article: the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal hypertension. Aliment Pharmacol Ther 8 (1994) 273-282
36. McCormick P.A., Greenslade L., Kibbler C.C., Chin J.K., Burroughs A.K., and McIntyre N. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 25 (1997) 833-836
37. Mitzner S.R., Stange J., Klammt S., Risler T., Erley C.M., Bader B.D., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl 6 (2000) 277-286
38. Moller S., and Henriksen J.H. Pathogenesis and pathophysiology of hepatorenal syndrome-is there scope for prevention?. Aliment Pharmacol Ther 20 Suppl 3 (2004) 31-41
39. Moller S., Henriksen J.H., and Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 284 (2003) G970-G979
40. Moreau R., and Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 43 (2006) 385-394
41. Moreau R., Durand F., Poynard T., Duhamel C., Cervoni J.-P., Ichai P., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2005) 923-930
42. Mulkay J.P., Louis H., Donckier V., Bourgeois N., Adler M., Deviere J., et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 64 (2001) 15-19
43. Nicholls K.M., Shapiro M.D., Kluge R., Chung H.-M., Bichet D.G., and Schrier R.W. Sodium excretion in advanced cirrhosis: effects of expansion of central blood volume blood volume and suppression of plasma aldosterone. Hepatology 6 (1986) 235-238
44. Ortega R., Gines P., Uriz J., Cardenas A., Calahorra B., De Las Heras D., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology 36 (2002) 941-948
45. Peak A.S., and Sheller A. Risk factors for developing gadolium-induced nephrogenic systemic fibrosis. Ann Pharmacother 41 (2007) 1481-1485
46. Pomier-Layrargues G., Paquin S.C., Hassoun Z., Lafortune M., and Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 38 (2003) 238-243
47. Restuccia T., Ortega R., Guevara M., Gines P., Alessandria C., Ozdogan O., et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatology 40 (2004) 140-146
48. Roberts S.E., Goldacre M.J., and Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 54 (2005) 1615-1621
49. Ruiz R., Barri Y.M., Jennings L.W., Chinnakatia S., Goldstein R.M., Levy M.F., et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 13 (2007) 838-843
50. Ruiz R., Kunitake H., Wilkinson A.H., Danovitch G.M., Farmer D.G., Ghobrial R.M., et al. Long-term analysis of combined liver and kidney transplantation at a single centre. Arch Surg 141 (2006) 735-741
51. Salerno F., Gerbes A.L., Gines P., Wong F., and Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56 (2007) 1310-1318
52. Salerno F., Camma C., Enea M., Rossle M., and Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133 (2007) 825-834
53. Schmid P.G., Abboud F.M., Wendling M.G., Ramberg E.S., Mark A.L., Haistad D.D., et al. Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 227 (1974) 998-1004
54. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., and Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
55. Solanki P., Chawla A., Garg R., Gupta R., Jain M., and Sarin S.K. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
56. Solis-Herruzo J.A., Duran A., Favela V., Caseellano G., Madrid J.L., Munoz-Yaque M.T., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 5 (1987) 167-173
57. Sort P., Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz-del-Arbol L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
58. Terra C., Guevara M., Torre A., Gilabert R., Fernandez J., Martin-Llahi M., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 129 (2006) 1944-1953
59. Treschan T.A., and Peters J. The vasopressin system: physiology and clinical strategies. Anesthesia 105 (2006) 599-612
60. Uriz J., Gines P., Cardenas A., Sort P., Jimenez W., Salmeron J.M., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2005) 43-48
61. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 (2004) 55-64
62. Wong F., Moore K., Dingenmanse J., and Jalan R. Lack of renal improvement with nonselective endothelin antagonism with Tezosentan in Type 2 hepatorenal syndrome. Hepatology 47 (2008) 160-168